NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...
Medical Marketing & Media9h
Roche strikes $5.3B obesity treatment deal with Zealand Pharma
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...
Trump’s Chips War Has Left Intel’s New CEO With a Near-Impossible Task. Here’s Why and 5 Other Things to Know Today.
Cooler February inflation doesn’t mean Fed will lower rates, promising obesity drug could challenge Novo Nordisk and Eli ...